|
1
|
Vaz J, Ansari D, Sasor A and Andersson R:
SPARC: A potential prognostic and therapeutic target in pancreatic
cancer. Pancreas. 44:1024–1035. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Spadi R, Brusa F, Ponzetti A, Chiappino I,
Birocco N, Ciuffreda L and Satolli MA: Current therapeutic
strategies for advanced pancreatic cancer: A review for clinicians.
World J Clin Oncol. 7:27–43. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lin QJ, Yang F, Jin C and Fu DL: Current
status and progress of pancreatic cancer in China. World J
Gastroenterol. 21:7988–8003. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Puleo F, Maréchal R, Demetter P, Bali MA,
Calomme A, Closset J, Bachet JB, Deviere J and Van Laethem JL: New
challenges in perioperative management of pancreatic cancer. World
J Gastroenterol. 21:2281–2293. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Davis JL, Pandalai PK, Ripley RT, Langan
RC and Avital I: Expanding surgical treatment of pancreatic cancer:
The role of regional chemotherapy. Pancreas. 41:678–684. 2014.
View Article : Google Scholar
|
|
6
|
Rachagani S, Macha MA, Heimann N,
Seshacharyulu P, Haridas D, Chugh S and Batra SK: Clinical
implications of miRNAs in the pathogenesis, diagnosis and therapy
of pancreatic cancer. Adv Drug Deliv Rev. 81:16–33. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tempero MA, Arnoletti JP, Behrman SW,
Ben-Josef E, Benson AB III, Casper ES, Cohen SJ, Czito B, Ellenhorn
JD, Hawkins WG, et al: Pancreatic Adenocarcinoma, version 2.2012:
Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw.
10:703–713. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Herman JM, Wild AT, Wang H, Tran PT, Chang
KJ, Taylor GE, Donehower RC, Pawlik TM, Ziegler MA, Cai H, et al:
Randomized phase III multi-institutional study of TNFerade biologic
with fluorouracil and radiotherapy for locally advanced pancreatic
cancer: Final results. J Clin Oncol. 31:886–894. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jones S, Zhang X, Parsons DW, Lin JC,
Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, et
al: Core signaling pathways in human pancreatic cancers revealed by
global genomic analyses. Science. 321:1801–1806. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hao J, Zhang S, Zhou Y, Hu X and Shao C:
MicroRNA 483-3p suppresses the expression of DPC4/Smad4 in
pancreatic cancer. FEBS Lett. 585:207–213. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Khan S, Ansarullah DK, Kumar D, Jaggi M
and Chauhan SC: Targeting microRNAs in pancreatic cancer:
Microplayers in the big game. Cancer Res. 73:6541–6547. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yu J, Li A, Hong SM, Hruban RH and Giggins
M: MicroRNA alterations of pancreatic intraepithelial neoplasias.
Clin Cancer Res. 18:981–992. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ali S, Saleh H, Sethi S, Sarkar FH and
Philip PA: MicroRNA profiling of diagnostic needle aspirates from
patients with pancreatic cancer. Br J Cancer. 107:1354–1360. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huang J, Liu J, Chen-Xiao K, Zhang X, Lee
WN, Go VL and Xiao GG: Advance in microRNA as a potential biomarker
for early detection of pancreatic cancer. Biomark Res. 4:202016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ma MZ, Kong X, Weng MZ, Cheng K, Gong W,
Quan ZW and Peng CH: Candidate microRNA biomarkers of pancreatic
ductal adenocarcinoma: Meta-analysis, experimental validation and
clinical significance. J Exp Clin Cancer Res. 32:712013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
He H, Hao SJ, Yao L, Yang F, Di Y, Li J,
Jiang YJ, Jin C and Fu DL: MicroRNA-218 inhibits cell invasion and
migration of pancreatic cancer via regulating ROBO1. Cancer Biol
Ther. 15:1333–1339. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hayes J, Peruzzi PP and Lawler S:
MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol
Med. 20:460–469. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang S, Hao J, Xie F, Hu X, Liu C, Tong
J, Zhou J, Wu J and Shao C: Downregulation of miR-132 by promoter
methylation contributes to pancreatic cancer development.
Carcinogenesis. 32:1183–1189. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Munding JB, Adai AT, Maghnouj A, Urbanik
A, Zöllner H, Liffers ST, Chromik AM, Uhl W, Szafranska-Schwarzbach
AE, Tannapfel A and Hahn SA: Global microRNA expression profiling
of microdissected tissues identifies miR-135b as a novel biomarker
for pancreatic ductal adenocarcinoma. Int J Cancer. 131:E86–E95.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhao C, Zhang J, Zhang S, Yu D, Chen Y,
Liu Q, Shi M, Ni C and Zhu M: Diagnostic and biological
significance of microRNA-192 in pancreatic ductal adenocarcinoma.
Oncology Rep. 30:276–284. 2013. View Article : Google Scholar
|
|
21
|
Zhang J, Zhao CY, Zhang SH, Yu DH, Chen Y,
Liu QH, Shi M, Ni CR and Zhu MH: Upregulation of miR-194
contributes to tumor growth and progression in pancreatic ductal
adenocarcinoma. Oncol Re. 31:1157–1164. 2014. View Article : Google Scholar
|
|
22
|
Abue M, Yokoyama M, Shibuya R, Tamai K,
Yamaguchi K, Sato I, Tanaka N, Hamada S, Shimosegawa T, Sugamura K
and Satoh K: Circulating miR-483-3p and miR-21 is highly expressed
in plasma of pancreatic cancer. Int J Oncol. 46:539–547. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Marine JC and Jochemsen AG: Mdmx as an
essential regulator of p53 activity. Biochem Biolphys Res Commun.
331:750–760. 2005. View Article : Google Scholar
|
|
24
|
Gospodarowicz MK, Brierley JD and
Wittekind C: TNM Classification of Malignant Tumours. 2017.
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delata Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner
MR, Frankel WL, Morgan DL, Postier RG, Brackett DJ and Schmittgen
TD: Expression profiling identifies microRNA signature in
pancreatic cancer. Int J Cancer. 120:1046–1054. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Szafranska AE, Davison TS, John J, Cannon
T, Sipos B, Maghnouj A, Labourier E and Hahn SA: MicroRNA
expression alterations are linked to tumorigenesis and
non-neoplastic processes in pancreatic ductal adenocarcinoma.
Oncogene. 26:4442–4452. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang Y, Li M, Wang H, Fisher WE, Lin PH,
Yao Q and Chen C: Profiling of 95 microRNAs in pancreatic cancer
cell lines and surgical specimens by real-time PCR analysis. World
J Surg. 33:698–709. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lee KH, Lee JK, Choi DW, Do IG, Sohn I,
Jang KT, Jung SH, Heo JS, Choi SH and Lee KT: Postoperative
prognosis prediction of pancreatic cancer with seven microRNAs.
Pancreas. 44:764–768. 2015. View Article : Google Scholar : PubMed/NCBI
|
